Drug utilization of biologic therapy in Crohn’s disease and ulcerative colitis: a population-based Danish cohort study 2015–2020

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769–2778.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB, Ulcerative colitis practice guidelines in adults: American College of gastroenterology. Am J Gastroenterol. 2010;105(3):501–523; quiz 524.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgrad Med. 2017;129(5):538–553.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Lo B, Vind I, Vester-Andersen MK, et al. Validation of ulcerative colitis and Crohn’s disease and their phenotypes in the Danish national patient registry using a population-based cohort. Scand J Gastroenterol. 2020;55(10):1171–1175.
   PubMed Web of Science ®Google Scholar
• Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017;45(7):961–972.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
   PubMed Web of Science ®Google Scholar
• Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7 Suppl):103–105.
   PubMed Web of Science ®Google Scholar
• Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7 Suppl):91–94.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the danish national prescription registry. Int J Epidemiol. 2017;46(3):798–798f.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Borgan Ø, Zhang Y. Using cumulative sums of martingale residuals for model checking in nested case-control studies. Biometrics. 2015;71(3):696–703.
   PubMed Web of Science ®Google Scholar
• medicinraadet.dk. Lægemiddelrekommandation med dyre lægemidler til behandling af kroniske inflammatoriske tarmsygdomme (IBD) - version 3.6. Available: https://medicinraadet.dk/arkiv/laegemiddelrekommandationer/mave-og-tarmsygdomme/kroniske-inflammatoriske-tarmsygdomme/kroniske-inflammatoriske-tarmsygdomme-3-6-rads-arkiv.
   Google Scholar
• Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an Epi-IBD study. J Crohns Colitis. 2019;13(2):198–208.
   PubMed Web of Science ®Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68(3):423–433.
   PubMed Web of Science ®Google Scholar
• Zhao M, Sall Jensen M, Knudsen T, et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study. Aliment Pharmacol Ther. 2022;55(5):541–557.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Tennakoon A, Leung S, et al. Factors associated with discontinuation of anti-TNF inhibitors among persons with IBD: a population-based analysis. Inflamm Bowel Dis. 2017;23(3):409–420.
   PubMed Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(5):811–817.e3.
   PubMed Web of Science ®Google Scholar
• Olivera P, Thiriet L, Luc A, et al. Treatment persistence for infliximab versus adalimumab in Crohnʼs disease: a 14-year single-center experience. Inflamm Bowel Dis. 2017;23(6):976–985.
   PubMed Web of Science ®Google Scholar
• Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis - Singh - 2016. - Alimentary Pharmacology & Therapeutics - Wiley Online Library. [cited 7 Jul 2021]. Available: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13580.
   Google Scholar
• Sah J, Teeple A, Muser E, et al. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Curr Med Res Opin. 2022;38(7):1093–1101.
   PubMed Web of Science ®Google Scholar
• Sassaki LY, Magro DO, Saad-Hossne R, et al. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). BMC Gastroenterol. 2022;22(1):268.
   PubMed Web of Science ®Google Scholar
• Bargo D, Tritton T, Cappelleri JC, et al. Living with ulcerative colitis in Japan: biologic persistence and health-care resource use. Inflamm Intest Dis. 2021;6(4):186–198.
   PubMedGoogle Scholar
• Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681.
   PubMed Web of Science ®Google Scholar
• Pudipeddi A, Ko Y, Paramsothy S, et al. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the persistence Australian national IBD cohort (PANIC) study. Therap Adv Gastroenterol. 2022;15:175628482210807.
   Web of Science ®Google Scholar
• vejledning-til-lpr3_f.pdf. Available: https://sundhedsdatastyrelsen.dk/-/media/sds/filer/forskerservice/vejledning-til-lpr3_f.pdf?la=da.
   Google Scholar
• Broe MO, Jensen PB, Mattsson TO, et al. Validity of antineoplastic procedure codes in the danish national patient registry: the case of colorectal cancer. Epidemiology. 2020;31(4):599–603.
   PubMed Web of Science ®Google Scholar
• Brady JE, Stott-Miller M, Mu G, et al. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509–1521.
   PubMed Web of Science ®Google Scholar
• Larsen L, Drewes AM, Broberg MCH, et al. Changing infliximab prescription patterns in inflammatory bowel disease: a population-based cohort study, 1999-2014. Inflamm Bowel Dis. 2018;24(2):433–439.
   PubMed Web of Science ®Google Scholar